Exploring the role of big data analytics and dynamic capabilities in ESG programs within pharmaceuticals

IF 1.7 3区计算机科学 Q3 COMPUTER SCIENCE, SOFTWARE ENGINEERING Software Quality Journal Pub Date : 2024-03-06 DOI:10.1007/s11219-024-09666-4

{"title":"Exploring the role of big data analytics and dynamic capabilities in ESG programs within pharmaceuticals","authors":"","doi":"10.1007/s11219-024-09666-4","DOIUrl":null,"url":null,"abstract":"<h3>Abstract</h3> <p>Achieving the United Nations’ Sustainable Development Goals (SDGs) requires environmental, social, and governance (ESG) programs in the pharmaceutical industry. Using the Millennium Development Goals, the 2030 agenda aims to transform European Union companies toward sustainability. In pharmaceuticals, in particular, ESG programs come with complexities such as employee skills, corporate goals, and management expectations. Managing these programs effectively requires advanced technologies such as big data analytics (BDA) and dynamic capabilities (DC). In this study, DC theory is used to develop an architecture for managing ESG criteria, focusing on provenance, traceability, and availability. BDA’s role in ESG programs is explored, along with its use cases and benefits, and how DC drives success in ESG implementation. The study examined five pharmaceutical companies in Germany, Portugal, and Switzerland, all consulting the same firm for BDA systems, to identify the characteristics of effective BDA implementation. The research explores how BDA and DC jointly enhance ESG efforts, the essential skills needed, and how DC aids in real-time decision-making in BDA projects aligned with ESG standards. It highlights the BDA system’s accuracy and effectiveness in managing ESG programs, with DC as a pivotal facilitator. Findings reveal BDA’s value in operational efficiency and aligning business models with ESG goals, underscoring the need for diverse skills in BDA implementation and DC’s importance in integrating various managerial capacities into effective strategies. The study promotes a dynamic, data-driven approach in the pharmaceutical industry for managing complex ESG initiatives. It stresses continuous learning, adaptation, and integrating technological advances with ethical business practices. The research concludes by emphasizing BDA and DC’s vital roles in advocating ethical, socially responsible, and environmentally sustainable practices in the pharmaceutical sector, marrying technology with ethical business strategies.</p>","PeriodicalId":21827,"journal":{"name":"Software Quality Journal","volume":"192 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Software Quality Journal","FirstCategoryId":"94","ListUrlMain":"https://doi.org/10.1007/s11219-024-09666-4","RegionNum":3,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"COMPUTER SCIENCE, SOFTWARE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Achieving the United Nations’ Sustainable Development Goals (SDGs) requires environmental, social, and governance (ESG) programs in the pharmaceutical industry. Using the Millennium Development Goals, the 2030 agenda aims to transform European Union companies toward sustainability. In pharmaceuticals, in particular, ESG programs come with complexities such as employee skills, corporate goals, and management expectations. Managing these programs effectively requires advanced technologies such as big data analytics (BDA) and dynamic capabilities (DC). In this study, DC theory is used to develop an architecture for managing ESG criteria, focusing on provenance, traceability, and availability. BDA’s role in ESG programs is explored, along with its use cases and benefits, and how DC drives success in ESG implementation. The study examined five pharmaceutical companies in Germany, Portugal, and Switzerland, all consulting the same firm for BDA systems, to identify the characteristics of effective BDA implementation. The research explores how BDA and DC jointly enhance ESG efforts, the essential skills needed, and how DC aids in real-time decision-making in BDA projects aligned with ESG standards. It highlights the BDA system’s accuracy and effectiveness in managing ESG programs, with DC as a pivotal facilitator. Findings reveal BDA’s value in operational efficiency and aligning business models with ESG goals, underscoring the need for diverse skills in BDA implementation and DC’s importance in integrating various managerial capacities into effective strategies. The study promotes a dynamic, data-driven approach in the pharmaceutical industry for managing complex ESG initiatives. It stresses continuous learning, adaptation, and integrating technological advances with ethical business practices. The research concludes by emphasizing BDA and DC’s vital roles in advocating ethical, socially responsible, and environmentally sustainable practices in the pharmaceutical sector, marrying technology with ethical business strategies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探索大数据分析和动态能力在制药企业 ESG 计划中的作用

摘要要实现联合国的可持续发展目标（SDGs），就必须在制药行业实施环境、社会和治理（ESG）计划。2030 年议程以千年发展目标为基础，旨在帮助欧盟企业实现可持续发展。特别是在制药行业，ESG 计划具有复杂性，如员工技能、企业目标和管理期望。有效管理这些项目需要大数据分析（BDA）和动态能力（DC）等先进技术。在本研究中，DC 理论被用于开发管理 ESG 标准的架构，重点关注出处、可追溯性和可用性。研究探讨了 BDA 在环境、社会和治理项目中的作用、使用案例和优势，以及动态能力如何推动环境、社会和治理的成功实施。该研究考察了德国、葡萄牙和瑞士的五家制药公司，这些公司都向同一家公司咨询了 BDA 系统，以确定有效实施 BDA 的特征。研究探讨了 BDA 和 DC 如何共同加强环境、社会和公司治理工作、所需的基本技能，以及 DC 如何在符合环境、社会和公司治理标准的 BDA 项目中协助实时决策。研究强调了 BDA 系统在管理 ESG 计划方面的准确性和有效性，而 DC 是其中的关键促进因素。研究结果揭示了 BDA 在提高运营效率和使业务模式与 ESG 目标相一致方面的价值，强调了在 BDA 实施过程中对各种技能的需求，以及 DC 在将各种管理能力整合到有效战略中的重要性。本研究提倡制药行业采用动态、数据驱动的方法来管理复杂的环境、社会和公司治理措施。它强调持续学习、适应以及将技术进步与商业道德实践相结合。研究最后强调了 BDA 和 DC 在倡导制药行业道德、社会责任和环境可持续发展实践方面的重要作用，并将技术与道德商业战略相结合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Software Quality Journal 工程技术-计算机：软件工程

CiteScore

4.90

自引率

5.30%

发文量

审稿时长

>12 weeks

期刊介绍： The aims of the Software Quality Journal are: (1) To promote awareness of the crucial role of quality management in the effective construction of the software systems developed, used, and/or maintained by organizations in pursuit of their business objectives. (2) To provide a forum of the exchange of experiences and information on software quality management and the methods, tools and products used to measure and achieve it. (3) To provide a vehicle for the publication of academic papers related to all aspects of software quality. The Journal addresses all aspects of software quality from both a practical and an academic viewpoint. It invites contributions from practitioners and academics, as well as national and international policy and standard making bodies, and sets out to be the definitive international reference source for such information. The Journal will accept research, technique, case study, survey and tutorial submissions that address quality-related issues including, but not limited to: internal and external quality standards, management of quality within organizations, technical aspects of quality, quality aspects for product vendors, software measurement and metrics, software testing and other quality assurance techniques, total quality management and cultural aspects. Other technical issues with regard to software quality, including: data management, formal methods, safety critical applications, and CASE.